Markets & Finance

First Albany Cuts Renovis to Neutral


From Standard & Poor's Equity Research

First Albany downgraded Renovis (RNVS) to neutral from buy, noting the research trials of the company's drug in development for treating ischemic stroke.

Analyst Lucy Lu says she has less confidence regarding the drug's efficacy, and doesn't feel comfortable having a buy recommendation on Renovis. Still, for the time being, she maintains her sales estimates.


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus